Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export

Nature Medicine

Volumn 18, Issue 2, 2012, Pages 291-295

  Lei, Peng ^a   Ayton, Scott ^a   Finkelstein, David I ^a   Spoerri, Loredana ^a,b   Ciccotosto, Giuseppe D ^a,b   Wright, David K ^a   Wong, Bruce X W ^a   Adlard, Paul A ^a   Cherny, Robert A ^a   Lam, Linh Q ^a   Roberts, Blaine R ^a   Volitakis, Irene ^a   Egan, Gary F ^a,c   McLean, Catriona A ^a   Cappai, Roberto ^a,b   Duce, James A ^a   Bush, Ashley I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CERULOPLASMIN; CLIOQUINOL; FERROPORTIN; IRON; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN REGION; CELL LOSS; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IRON TRANSPORT; KNOCKOUT MOUSE; LIVER; MALE; MOUSE; NERVE CELL CULTURE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; TAUOPATHY;

AGE FACTORS; AGED; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; BRAIN CHEMISTRY; CERULOPLASMIN; DEMENTIA; HUMANS; IRON; MALE; MICE; MICE, KNOCKOUT; PARKINSONIAN DISORDERS; TAU PROTEINS;

MUS;

EID: 84856708923     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2613     Document Type: Article

References (33)

1. Laws, S.M. et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol. Psychiatry 12, 510-517 (2007). (Pubitemid 46652455)
2. Laws, S.M. et al. Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. Neurobiol. Aging 29, 1276-1278 (2008). (Pubitemid 351822412)
3. Lei, P. et al. Tau protein: relevance to Parkinson's disease. Int. J. Biochem. Cell Biol. 42, 1775-1778 (2010).
4. Höglinger, G.U. et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699-705 (2011).
5. Lee, V.M.-Y., Goedert, M. & Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001). (Pubitemid 32695256)
6. Smith, M.A., Harris, P.L., Sayre, L.M. & Perry, G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94, 9866-9868 (1997). (Pubitemid 27408156)
7. Duce, J.A. et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142, 857-867 (2010).
8. Bartzokis, G. et al. MRI evaluation of brain iron in earlier-and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 17, 213-222 (1999). (Pubitemid 29053180)
9. Zecca, L., Youdim, M.B., Riederer, P., Connor, J.R. & Crichton, R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873 (2004). (Pubitemid 39482155)
10. Oakley, A.E. et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68, 1820-1825 (2007). (Pubitemid 46791395)
11. Dexter, D.T., Jenner, P., Schapira, A.H. & Marsden, C.D. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32 (suppl.), S94-S100 (1992).
12. Paisán-Ruiz, C. et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol. Aging (in the press).
13. Khatoon, S., Grundke-Iqbal, I. & Iqbal, K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett. 351, 80-84 (1994).
14. Ksiezak-Reding, H., Binder, L.I. & Yen, S.-H.C. Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer's disease brains with Alz 50 and Tau-1. J. Biol. Chem. 263, 7948-7953 (1988).
15. Zhukareva, V. et al. Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol. 105, 469-476 (2003). (Pubitemid 36798843)
16. Mandel, S.A. et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 14, 46-60 (2005). (Pubitemid 40868983)
17. Kaur, D. et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909 (2003). (Pubitemid 36398297)
18. Dawson, H.N. et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114, 1179-1187 (2001). (Pubitemid 32288531)
19. Harada, A. et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488-491 (1994). (Pubitemid 24210568)
20. Ikegami, S., Harada, A. & Hirokawa, N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci. Lett. 279, 129-132 (2000). (Pubitemid 30069810)
21. Roberson, E.D. et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007). (Pubitemid 46717684)
22. Ittner, L.M. et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397 (2010).
23. Cookson, M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52 (2005). (Pubitemid 40995500)
24. O'Neill, J. et al. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov. Disord. 17, 917-927 (2002). (Pubitemid 36040996)
25. Dauer, W. & Przedborski, S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003). (Pubitemid 37130207)
26. Sedelis, M., Schwarting, R.K. & Huston, J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125, 109-125 (2001). (Pubitemid 33000449)
27. Smith, M.A. et al. Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease. Nat. Med. 1, 365-369 (1995).
28. Stamer, K., Vogel, R., Thies, E., Mandelkow, E. & Mandelkow, E.-M. Tau blocks traffic of organelles, neurofilaments and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051-1063 (2002). (Pubitemid 34839854)
29. Rogers, J.T. et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45518-45528 (2002). (Pubitemid 36159162)
30. Ramsden, M. et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 25, 10637-10647 (2005). (Pubitemid 41681911)
31. Lewis, J. et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405 (2000). (Pubitemid 32983430)
32. Ittner, L.M. et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. USA 105, 15997-16002 (2008).
33. Przedborski, S. et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274 (2001). (Pubitemid 32198231)